Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript

Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript

Seeking Alpha • 2 hours ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

GlobeNewsWire • 12 hours ago

What's Going On With Beam Therapeutics Stock?

Beam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectations of $12.567 million.

Benzinga • 5 hours ago

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago.

Zacks Investment Research • 9 hours ago

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD) CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD).

GlobeNewsWire • 12 hours ago

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

GlobeNewsWire • Feb 23, 2026

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933

Bethany J. Cavanagh sold 6,198 direct shares for a transaction value of approximately $216,933 at a weighted average price of around $35.00 per share. The sale represented 15.11% of direct post-transaction holdings, reducing direct ownership from 41,011 to 34,813 shares.

The Motley Fool • Feb 1, 2026

Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises

Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.

Zacks Investment Research • Jan 13, 2026

Beam Therapeutics: Pivoting From Platform To Execution Stage

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Risto-cel targets Sickle Cell Disease but faces a crowded ex vivo market; best-in-class data and BLA submission are expected by end of 2026.

Seeking Alpha • Jan 13, 2026